Modeling, simulation firm supporting radiation countermeasure development

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/BreakingTheWalls)
(Image: Getty/BreakingTheWalls)

Related tags Modeling and simulation

The modeling and simulation solutions provider Simulations Plus has been contracted to support countermeasure development for acute radiation syndrome in a partnership with a global pharma company.

An SLP company, DILIsym Services (DSS), is leading the development of RADAsym, a new quantitative systems pharmacology (QPS) platform.

Cognigen also will be working directly with the sponsor to curate data and support pharmacometric modeling activities.

The technology helps predict the effects of radiation in mice, non-human primates, and humans, in addition to the efficacy of interventions.

It will be used to help support approval for acute radiation syndrome (ARS) treatment under the Animal Rule, regulations which enable the approval of drugs and licensure of biological products in situations where human efficacy studies are not ethical or feasible.

The QPS platform will include major biological systems, including the vasculature and immune systems, the liver and GI tract, as well as the lung and bone marrow.

In the future, the RADAsym platform will be available for licensing and consulting services.

Said Shawn O’Connor, Simulations Plus CEO: "We are pleased to have been engaged by industry to support this critical development effort. Our expertise across QSP and PKPD techniques and model development positions us uniquely to satisfy the requirements of this endeavor. This engagement also demonstrates our ability to cross-sell the capabilities of our divisions.”

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

Related suppliers

Follow us


View more